Alembic Pharmaceuticals Limited has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg. The approval strengthens the company’s growing presence in the regulated US generics market and adds another important product to its portfolio.
The approved product is therapeutically equivalent to the reference listed drug, Gilenya Capsules, 0.5 mg, marketed by Novartis Pharmaceuticals Corporation. Fingolimod is prescribed for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in patients aged 10 years and above.
Multiple sclerosis is a chronic neurological condition that affects the central nervous system and can lead to disability if left untreated. Fingolimod belongs to the sphingosine 1-phosphate receptor modulator class and is used to help reduce disease activity and slow progression in eligible patients.
According to IQVIA data, Fingolimod Capsules, 0.5 mg, recorded an estimated market size of US$145 million for the twelve months ending December 2025, offering a meaningful commercial opportunity for Alembic in the US market. With this latest approval, Alembic now has a cumulative total of 237 ANDA approvals from the USFDA, comprising 219 final approvals and 18 tentative approvals. The milestone reflects the company’s continued focus on product development, regulatory compliance and expanding its global generics business.
Alembic Pharmaceuticals is a vertically integrated research-driven pharmaceutical company with a legacy dating back to 1907. Headquartered in India, the company manufactures and markets generic medicines across several international markets. Its manufacturing and research facilities are approved by leading global regulatory authorities, including the USFDA.
The company is also a major player in India’s branded generics segment, supported by a wide portfolio of established brands and a strong field presence across the country. Through sustained investments in manufacturing, research and quality systems, Alembic continues to strengthen its role in domestic and international healthcare markets.
Industry analysts note that approvals for complex and specialty therapies such as Fingolimod demonstrate increasing capabilities among Indian pharmaceutical manufacturers in addressing high-value therapeutic segments. The availability of additional generic options can also help improve affordability and patient access in regulated markets.
The latest approval is expected to support Alembic’s growth strategy in the United States while reinforcing confidence in its product pipeline. As competition intensifies in the global generics sector, companies with robust regulatory track records and diversified product offerings are likely to remain well positioned. Alembic’s expanding portfolio of USFDA-approved products underlines its long-term commitment to quality manufacturing, scientific innovation and delivering accessible medicines to patients worldwide.
